🔓 Unlock the full profile of Oliver Dodd (Nucleate), including verified contact details, financial insights, and professional associations.
See Oliver Dodd Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: oli*****@nuc******.com
Mobile: 75474*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Oliver Dodd currently serves as the COO and Co-Founder of Nucleate, an organization established in 2019 that focuses on empowering the biotechnology community.
- Since the founding of Nucleate, the organization has experienced notable growth, with a 28.2% increase in headcount over the past two years, indicating a strong impact in the biotech sector.
- Dodd is pursuing a PhD at Harvard University, indicating a commitment to advancing knowledge within the field, with an expected completion by November 2024.
- Previously, Dodd held roles such as Associate at Petri and Research Associate at FVL59, showcasing a progression through various research and development positions within biotechnology.
- Dodd co-founded Remora Therapeutics, serving as CEO, emphasizing a strong entrepreneurial spirit and focus on therapeutics innovation.
- Experience at Koch Institute for Integrative Cancer Research and the Broad Institute, among others, contributes to a robust background in cancer research and systems biology.
- Prior to significant leadership roles, Dodd gained foundational experience as an Undergraduate Research Assistant and Research Assistant, underpinning a deep understanding of scientific research methodologies.
- Nucleate emphasizes collaboration and education in the biotech landscape, demonstrating Dodd's commitment to fostering innovation and community engagement.